First-line treatment of stage IV non-small-cell lung cancer (NSCLC) has evolved from chemotherapy alone to chemotherapy, targeted therapy, and immunotherapy (1), and targeted therapy for patients with positive mutations in driver Genes, such as human epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK)/C-ros oncogene 1 receptor tyrosine kinase (ROS1) and T790M, has been shown to significantly prolong progression-free survival (PFS) (2–5). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.